(Q33871466)

English

Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics

scientific article published in 2000

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics (English)

1 reference

Europe PubMed Central

29 July 2017

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

Nightingale CH

1

1 reference

Europe PubMed Central

29 July 2017

language of work or name

0 references

publication date

1 March 2000

1 reference

Europe PubMed Central

29 July 2017

Pharmacotherapy

1 reference

Europe PubMed Central

29 July 2017

20

1 reference

Europe PubMed Central

29 July 2017

3

1 reference

Europe PubMed Central

29 July 2017

245-256

1 reference

Europe PubMed Central

29 July 2017

Does the use of antimicrobial agents in veterinary medicine and animal husbandry select antibiotic-resistant bacteria that infect man and compromise antimicrobial chemotherapy?

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

Results of the Alexander Project: a continuing, multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

In vitro activity of grepafloxacin and 25 other antimicrobial agents against Streptococcus pneumoniae: correlation with penicillin resistance.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

Structure-activity and structure-side-effect relationships for the quinolone antibacterials

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

The in-vitro activity of moxifloxacin against Legionella species and the effects of medium on susceptibility test results.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

Expanded activity and utility of the new fluoroquinolones: a review

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopy

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

Bactericidal properties of moxifloxacin and post-antibiotic effect.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

Identifiers

10.1592/PHCO.20.4.245.34880

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33871466&oldid=2143854078"